Cue Biopharma - CUE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.00
  • Forecasted Upside: 412.82%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.56
▼ -0.02 (-1.27%)

This chart shows the closing price for CUE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cue Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CUE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CUE

Analyst Price Target is $8.00
▲ +412.82% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Cue Biopharma in the last 3 months. The average price target is $8.00, with a high forecast of $10.00 and a low forecast of $6.00. The average price target represents a 412.82% upside from the last price of $1.56.

This chart shows the closing price for CUE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Cue Biopharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/9/2024Stifel NicolausReiterated RatingBuy ➝ Buy$8.00Low
4/9/2024OppenheimerReiterated RatingOutperform ➝ Outperform$10.00Low
4/3/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$8.00Low
3/13/2024Jefferies Financial GroupInitiated CoverageBuy$6.00Low
11/6/2023Piper SandlerBoost TargetOverweight ➝ Overweight$7.00 ➝ $8.00Low
3/22/2023Stifel NicolausLower TargetBuy$9.00 ➝ $8.00Low
3/22/2023OppenheimerReiterated RatingOutperform$10.00Low
11/20/2022Piper SandlerInitiated CoverageOverweight$7.00Low
8/24/2022OppenheimerLower TargetOutperform$26.00 ➝ $10.00Low
3/23/2022JMP SecuritiesLower TargetBuy$30.00 ➝ $15.00Medium
3/21/2022OppenheimerLower TargetOutperform$32.00 ➝ $26.00Medium
3/18/2022Craig HallumLower TargetBuy$28.00 ➝ $26.00High
1/13/2022HC WainwrightInitiated CoverageBuy$20.00High
1/3/2022Craig HallumInitiated CoverageBuy$28.00High
11/17/2021JMP SecuritiesReiterated RatingBuy$29.00Low
5/20/2021Robert W. BairdReiterated RatingBuy$28.00High
5/13/2021Robert W. BairdReiterated RatingBuy$28.00Low
3/17/2021Berenberg BankReiterated RatingBuy$30.00High
11/24/2020Berenberg BankInitiated CoverageBuy$30.00High
9/1/2020OppenheimerReiterated RatingBuy$32.00High
6/7/2020OppenheimerReiterated RatingBuy$32.00High
5/20/2020Stifel NicolausBoost TargetBuy$25.00 ➝ $30.00High
5/20/2020BTIG ResearchBoost TargetPositive ➝ Buy$26.00 ➝ $33.00High
5/20/2020OppenheimerBoost TargetOutperform$27.00 ➝ $32.00High
4/21/2020Stifel NicolausBoost TargetBuy$21.00 ➝ $25.00Low
4/20/2020OppenheimerReiterated RatingBuy$27.00Low
4/8/2020Stifel NicolausInitiated CoverageBuy$21.00High
3/6/2020JMP SecuritiesBoost TargetOutperform$22.00 ➝ $30.00High
2/24/2020OppenheimerInitiated CoverageOutperform$27.00Low
1/28/2020BTIG ResearchInitiated CoverageBuyLow
1/22/2020JMP SecuritiesInitiated CoverageOutperformMedium
7/25/2019Robert W. BairdInitiated CoverageOutperform$13.00High
(Data available from 4/21/2019 forward)

News Sentiment Rating

-0.02 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/23/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/23/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/22/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/22/2023
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/21/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/20/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/21/2024
  • 0 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
4/20/2024

Current Sentiment

  • 0 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Cue Biopharma logo
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $1.56
Low: $1.52
High: $1.61

50 Day Range

MA: $1.95
Low: $1.50
High: $2.55

52 Week Range

Now: $1.56
Low: $1.47
High: $5.12

Volume

169,010 shs

Average Volume

252,020 shs

Market Capitalization

$75.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.02

Frequently Asked Questions

What sell-side analysts currently cover shares of Cue Biopharma?

The following Wall Street research analysts have issued stock ratings on Cue Biopharma in the last year: Jefferies Financial Group Inc., Oppenheimer Holdings Inc., Piper Sandler, and Stifel Nicolaus.
View the latest analyst ratings for CUE.

What is the current price target for Cue Biopharma?

4 Wall Street analysts have set twelve-month price targets for Cue Biopharma in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 412.8%. Oppenheimer Holdings Inc. has the highest price target set, predicting CUE will reach $10.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $6.00 for Cue Biopharma in the next year.
View the latest price targets for CUE.

What is the current consensus analyst rating for Cue Biopharma?

Cue Biopharma currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CUE will outperform the market and that investors should add to their positions of Cue Biopharma.
View the latest ratings for CUE.

What other companies compete with Cue Biopharma?

How do I contact Cue Biopharma's investor relations team?

Cue Biopharma's physical mailing address is 21 ERIE STREET, CAMBRIDGE MA, 02139. The company's listed phone number is (617) 949-2680 and its investor relations email address is [email protected]. The official website for Cue Biopharma is www.cuebiopharma.com. Learn More about contacing Cue Biopharma investor relations.